share_log

Eden Unveils the World's First Compounded GLP-1 Rx Gummy

Eden Unveils the World's First Compounded GLP-1 Rx Gummy

伊甸園推出全球首款複合GLP-1處方軟糖
PR Newswire ·  2024/12/31 10:51

DENVER, Dec. 31, 2024 /PRNewswire/ -- Eden (tryeden.com) has launched the world's first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format, this innovative format reimagines how individuals approach GLP-1 programs in the United States. Eden believes a healthier you means more unforgettable moments. They're tackling America's metabolic health crisis with personalized care and transformative solutions.

丹佛,2024年12月31日 /PRNewswire/ -- Eden (tryeden.com) 推出了全球首款複方西馬魯肽軟糖。此款創新產品旨在以方便的無針格式提供GLP-1藥物的益處,重新定義了個人在美國如何接受GLP-1方案。Eden相信,更健康的你意味着更多難忘的時刻。他們正在通過個性化的關懷和變革性的解決方案來應對美國的代謝健康危機。

Eden (tryeden.com) has launched the world's first compounded semaglutide gummy.
Eden (tryeden.com) 推出了全球首款複方西馬魯肽軟糖。

This first of its kind GLP-1 gummy provides the same active ingredient as compounded semaglutide, making it easier than ever for individuals to incorporate this medication into their daily routines if prescribed by Eden's network of healthcare providers.

這款首創的GLP-1軟糖提供與複方西馬魯肽相同的活性成分,使個人在與Eden的醫療服務提供者處方的情況下,更容易將這種藥物納入他們的日常生活中。

"At Eden, we are committed to making transformative healthcare accessible and convenient," said Josh Khan, President of Eden. "With this first-of-its-kind gummy, we've removed barriers like needles and discomfort, empowering individuals to explore personalized care programs with their healthcare providers to achieve their health goals with a format that fits into their lives."

Eden總裁喬什·哈恩(Josh Khan)表示:"在Eden,我們致力於讓變革性的醫療服務變得可及且方便。憑藉這種首創的軟糖,我們消除了針頭和不適等障礙,賦予個人與醫療服務提供者共同探索個性化護理方案的能力,以實現他們的健康目標,從而融入生活的格式。"

This gummy is not only a first in its field but also addresses the growing demand for more user-friendly alternatives to traditional medications. Research shows that 76% of individuals prefer oral options over injections. Eden seeks to fulfil their patient's desire for a more palatable, easier option than oral semaglutide droppers.

這款軟糖不僅是該領域的首款產品,而且還滿足了對傳統藥物更便捷替代品日益增長的需求。研究顯示,76%的個人更傾向於口服藥物而不是注射。Eden旨在滿足患者對比口服西馬魯肽滴劑更可口、更容易的選擇的需求。

In addition to the innovative format, Eden connects patients to a network of healthcare providers through a doctor-led weight loss program. Members gain access to 24/7 personalized medical consultations, custom care plans, on-demand workouts, and tailored meal plans to support their metabolic health journey.

除了這種創新格式外,Eden還通過醫生主導的減肥計劃將患者與醫療服務提供者網絡連接起來。會員可以獲得全天候個性化醫療諮詢、自定護理計劃、隨需隨地的鍛鍊計劃和量身定製的飲食計劃,以支持他們的代謝健康之旅。

"Eden is at the forefront of metabolic health innovation," said Adam McBride, CEO of Eden. "With this gummy format, we're improving access and empowering individuals to take control of their health. It's a game changer."

Eden首席執行官亞當·麥克布賴德(Adam McBride)表示:"Eden正站在代謝健康創新的最前沿。通過這種軟糖格式,我們正在改善獲取方式,並賦予個人掌握自己健康的能力。這是一個遊戲改變者。"

The compounded semaglutide gummy is available through subscription plans starting at $246 per month. Patients must consult with a licensed physician to determine eligibility for treatment. Visit [ ] to learn more about this innovative offering and Eden's commitment to expanding access to care.

複方塞馬魯肽軟糖可通過訂閱計劃獲得,起價爲每月246美元。患者必須諮詢持牌醫生以判斷治療的資格。訪問[ ]以了解有關這一創新產品的更多信息,以及Eden在擴大醫療服務可及性方面的承諾。

About Eden
Eden is a digital health company focused on connecting patients with doctors and licensed compounding pharmacies to deliver personalized metabolic health programs. Trusted by over 50,000 members, Eden's goal is to make healthcare accessible and supportive for individuals seeking to improve how they look, feel, and perform.

關於Eden
Eden是一家專注於將患者與醫生和持牌複合藥房連接的互聯網醫療公司,旨在提供個性化的新陳代謝健康計劃。Eden的目標是使醫療服務對尋求改善外貌、感覺和表現的個人更加可及和支持,深受超過50,000名成員的信賴。

SOURCE Eden

來源:Eden

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?

440k+
440k+

Newsrooms &
新聞編輯室和

Influencers
意見領袖
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
已選擇加入
GET STARTED
開始

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論